A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".
Deadline for manuscript submissions: 26 October 2024
"Irritable bowel syndrome (IBS) is a highly prevalent gastrointestinal disease that represents a significant cause of morbidity worldwide. The disease significantly affects patients’ quality of life, work productivity and social functioning. The pathophysiology of IBS is not completely understood and its diagnosis should be made based on the Rome IV criteria. Nevertheless, the severity of the patient’s symptoms and concerns sometimes drives the physician to perform useless and/or expensive diagnostic tests, transforming IBS into a diagnosis of exclusion. Therefore, a deeper knowledge of IBS mechanisms is mandatory to improve the management of the disease. Conventional treatments include lifestyle changes, diets, probiotics, laxatives, antidiarrhoeals and antispasmodics. More recently, other therapies have been investigated in randomized controlled trials and observational studies, including faecal microbiota transplantation, central neuromodulators, intestinal secretagogues, drugs acting on opioid or 5-HT receptors, minimally absorbed antibiotics, and psychological therapies.
The scientific community will certainly benefit from updated reviews focusing on the optimal management of IBS. In this Special Issue, we invite you to submit your updated review addressing the management aspects and/or therapeutics of IBS."
Source: mdpi.com/journal/jcm/specia...